CSL – UBS rates the stock as Buy

By Broker News | More Articles by Broker News

UBS observes 139m flu vaccine doses have been distributed for the US flu season till October 9, up 9% versus last year. CSL also reported having increased its supply of flu vaccine into the US to circa 60m doses for the 20-21 season, a 20% increase from last year.

UBS anticipates a prolonged flu season and expects flu vaccine penetration rate in the US to rise with higher demand due to risks related to covid-19. Seqirus looks  well placed to benefit from this and UBS expects its revenues to increase by 17% in FY21.

UBS makes no changes to the Buy rating or $346 price target.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $346.00.Current Price is $302.78. Difference: $43.22 – (brackets indicate current price is over target). If CSL meets the UBS target it will return approximately 12% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →